 
 
 
 
CT-DBS for Traumatic Brain Injury Using the Medtronic Activa PC+S 
System   
Study Protocol and Statistical Analysis Plan  
[STUDY_ID_REMOVED]  
January 30, 2020 
CONFIDENTIAL   Page 1 of 39 Study Protocol 
 
Title:  CT-DBS for Traumatic Brain Injury  Using 
Medtronic Activa PC  and Percept  PC 
Type and Phase:  Single arm, single center feasibility study  
Study Product:  Medtronic Activa PC system , Medtronic Percept PC 
system  and Medtronic Nexus-E system for central 
thalamic deep brain stimulation (CT -DBS)  
Sponsor /Investigator  Jaim ie M. Henderson, MD  
Department of Neurosurgery  
Stanford University School of Medicine 
300 Pasteur Dr.  
Edwards Bldg/R -227 
Stanford, CA  94305 Phone: 650.723.5574 Fax: 650.725.8279  
henderj@stanford.edu  
 
Protocol Rev  Issue Date  
1.0 January 28, 2016  
2.0 February 21, 2017  
3.0 June 15, 2017  
4.0 December 18, 2017  
5.0 June 5, 2018  
6.0 June 1 7, 2019  
7.0 Jan 30, 2020  
8.0 TBD  
 
 
  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 2 of 39 TABLE OF CONTENTS  
TABLE OF CONTENTS  ..............................................................................................................2  
LIST OF ABBREVIATIONS  .......................................................................................................4  
1. SYNOPSIS  ............................................................................................................................5  
2. INTRODUCTION  ................................................................................................................7  
2.1. Traumatic Brain Injury  ......................................................................................................8  
2.2. Rationale for Proposed Study ............................................................................................9  
2.3. Rationale for CT/DBS  .....................................................................................................10  
2.4. Neuropsychological impairment following moderate to severe TBI: Target 
patient population .....................................................................................................11  
2.5. Role of frontostriatal systems in supporting sustained attention, working 
memory and processing speed  ..................................................................................11  
2.6. Role of central thalamus in pathophysiology of moderate to severe TBI .......................12  
3. STUDY OBJECTIVES  ......................................................................................................12  
4. STUDY DESIGN ................................................................................................................12  
5. STUDY DEVICE ................................................................................................................12  
6. STUDY PLAN  ....................................................................................................................13  
6.1. Study Population .............................................................................................................14  
6.1.1.  Inclusion Criteria  .................................................................................................14  
6.1.2.  Exclusion Criteria  ................................................................................................15  
6.1.3.  Concomitant Medications ....................................................................................15  
6.2. Informed Consent ............................................................................................................16  
6.3. Randomization to Multiple Baseline Condition and Treatment Withdrawal ..................16  
6.4. Screening Imaging  ...........................................................................................................17  
6.5. Screening and Preoperative Baseline Evaluation ............................................................17  
6.6. Inpatient Hospital Stay  ....................................................................................................17  
6.6.1.  Stage I:  Bilateral DBS Lead Implantation  ..........................................................17  
6.6.2.  Stage II  .................................................................................................................19  
6.7. Post-Surgical Washout Phase  ..........................................................................................20  
6.8. DBS Stimulation Titration/Optimization  ........................................................................20  
6.9. Unblinded Treatment Phase ............................................................................................20  
6.10.  DBS S timulation Long- term Continuation  .................................................................20  
6.11.  Six Month Open Label Follow -Up Period ..................................................................20  
6.12.  Unscheduled Visits: ....................................................................................................21  
7. DESCRIPTION OF OUTCOME ASSESSMENTS  ........................................................21  
7.1. Measures of Cognition ....................................................................................................21  
7.2. Physical Symptoms (self- report)  .....................................................................................21  
7.3. Psychological Health (self-report) ...................................................................................22  
7.4. Quality of Life (self- report)  .............................................................................................22  
7.5. Global Functional Outcome Measure  ..............................................................................22  
7.6. Participant Interview  .......................................................................................................23  
7.7. Exploratory Measures  ......................................................................................................23  
7.7.1.  Electrophysiological ............................................................................................23  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 3 of 39 8. EARLY WITHDRAWAL OR TERMINATION ............................................................24  
9. ADVERSE EVENTS  ..........................................................................................................24  
9.1. Adverse Event Identification and Assessment  ................................................................24  
9.2. Adverse Device Effect  .....................................................................................................24  
9.3. Serious Adverse Events (SAEs)  ......................................................................................25  
9.4. Anticipated & Unanticipated (UADEs) Adverse Device Effects  ....................................25  
9.4.1.  Anticipated Adverse Events  ................................................................................25  
9.4.2.  Unanticipated adverse device effects (UADEs)  ..................................................28  
9.5. Adverse Event Reporting ................................................................................................28  
9.5.1.  Reporting Serious Adverse Events ......................................................................29  
9.5.2.  Reporting UADEs ...............................................................................................29  
9.5.3.  Stopping Rules .....................................................................................................29  
9.5.4.  Reporting Deaths and Suicides ............................................................................29  
10. CLINICAL OVERSIGHT COMMITTEE  ......................................................................29  
10.1.  Medical Monitor  .........................................................................................................30  
11. STATISTICAL PLAN  .......................................................................................................30  
12. RISK ASSESSMENT AND MITIGATION ....................................................................30  
12.1.  Known and Anticipated Surgical Risks ......................................................................30  
12.2.  Device-Related and Therapy- Related Risks ...............................................................31  
12.3.  Protocol for Managing Suicidal Ideation and Intent ...................................................31  
13. ADMINISTRATIVE REQUIREMENTS, INCLUDING INVESTIGATOR 
RESPONSIBILITIES  ...............................................................................................33  
13.1.  Good Clinical Practice (GCP)  ....................................................................................33  
13.2.  Ethical Considerations  ................................................................................................33  
13.3.  Subject Information and Informed  Consent ...............................................................33  
13.4.  Subject Confidentiality  ...............................................................................................33  
13.5.  Protocol Compliance ..................................................................................................33  
13.6.  Maintenance of Study Records ...................................................................................34  
13.7.  Study Monitoring ........................................................................................................34  
13.8.  On-Site Audits  ............................................................................................................34  
13.9.  Case R eport Form Completion  ...................................................................................34  
13.10.  Study Product Accountability ..................................................................................35  
14. REFERENCES  ...................................................................................................................35  
APPENDIX 1.  DEVICE PROGRAMMING SOP  ..........................................................38  
 
 
  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 4 of 39 LIST OF ABBREVIATIONS  
Abbreviation  Definition  
AE Adverse Event  
SAE  Serious Adverse Event  
UADE  Unanticipated Device Event  
CT-DBS  Central Thalamus -Deep Brain Stimulation  
GOSE  Glasgow Outcome Scale -Extended  
MCS  Minimally Conscious State  
IPG Implantable Pulse Generator  
EMCS  Emergence from Minimally Conscious State  
SMTBI Moderate to severe  Traumatic Brain Injury  
GPi Internal Globus Pallidus  
STN  Subthalamic Nucleus  
VPM  Ventral Posterior Medial  
CRF  Case Report Form  
eCRF  Electronic Case Report Form  
INS Implantable Neurostimulator  
IC Integrated Circuit  
PIC Algorithm Microprocessor  
ANT  Attention Network Test  
PRO  Patient -Reported Outcomes  
  
  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 5 of 39 1. SYNOPSIS  
Table  1: Protocol Synopsis  
Title Central Thalamic Deep Brain Stimulation for the Treatment of Traumatic Brain 
Injury 
Study Groups Single arm study of 6 subjects  
Study Objective  Pilot study to in form the  safety an d efficacy of central thalamic-deep bra in 
stimula tion (CT-DBS) in the  treatm ent of chronic cognitive  impairme nt and 
residual disability cause d by tra umatic brain inju ry (TBI). 
Study Device  Medtronic Percept PC system for central thalamic  deep brain stimula tion (CT-
DBS) 
Clinical Hypothesis  CT-DBS will be safe in the study population and will enhance cognitive function as indexed by the primary outcome measure  
Study Population  Adult patients w ith a histo ry of moderate to severe TBI (GCS ≤12) who c ontinue  
to demonst rate neur opsyc hological impairme nt and functional disability 
(Glasgow Ou tcome Scale- Exte nded = 5-7) a t least 24 months post -injur y. The  6 
participants will be  separated into th ree pair s. 
Study Design  Single arm, open -label, sponsor -investigator study  
Number of Sites  1 site  
Total Number of Subjects  18 subjects screened with a total of 6 subjects enrolled for randomization and  
implantation 
Duration of Study  The total duration of the study is 12 to 14 months depending on cohort.  
Inclusion Criteria  • History of  moderate to severe  TBI based on worst GCS score within first 48 
hours of injury (acceptable GCS range = 3 -12) 
• Age 22-60 
• At least 24 months from d ate of onset  
• Fluent in En glish a nd able to ind ependently provide consent 
• Retains decision -making capacity and is able to function independently (i .e., 
unsupervised) in the home setting 
• Multiple unsuccessful attempts to sustain competitive employment or complete an academic degree- granting program of study 
• Either receives no CNS stimulants or other medications known to affect 
cognitive function, or on stable doses of these medications for the last three 
months (see additional information regarding concomitant medications 
below)  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 6 of 39 Exclusion Criteria  • Histo ry of major deve lopmental, neurologic, psychiatric or subst ance use 
disorder with evidence of disability pr ior to onse t of TBI 
• Major medical co- morbidities including: end st age renal failure, severe h eart 
failure, coag ulopath y, severe respi ratory pr oblems, severe liv er failure, 
uncontrolled hypertension or other sig nificant m edical co mo rbiditi es 
• Have had a documented seizure within 3 months of study screening (subjects 
may re -screen if seizure free after initial screen failure)  
• Malignancy with <  5 years life exp ectancy 
• Untreate d / unc ontrolled (severe a t the time of enrollment) depression or  
other psychiatric disorder 
• Women of childb earing age who do not reg ularly use a n accepted 
contraceptive m ethod 
• Inability to stop anticoagulation therapy or platelet anti-aggrega tion th erapy 
before, during and after surgery 
• Previ ous D BS or other brain impla nts 
• Previous a blative intracranial surgery 
• Implantable h ardware no t compatible with M RI 
• Condition requiring diathermy after DBS implantation  
• Hardware, lesions or  other fac tors limiting  placeme nt of electrode s in optim al 
target location in the  judgme nt of the opera ting surge on 
• Concu rrent enrollment in any other c linical trial 
• Any c ondition or finding tha t, in the  judgme nt of the PI , signifi cantly 
increase s risk or significantly reduces t he likelihood of  benefit from DBS 
Main Study Phases/Activities  • Pre-screening Evaluation and Informed Consent  
• Randomization to 1of 3 baseline conditions lasting 30, 44 or 58 days.  Each 
participant will also be randomly assigned to a treatment withdrawal or 
continuation condition for 21 days following the 90- day unblinded treatment 
phase 
• Baseline p hysical and neurological pre -operative examinations  
• Hospitalization and surgical implantation of DBS system  
• Post-operative washout (30-day surgical washout for resolution of any 
transient physiological or behavioral  effects of surgery) 
• DBS Stimulation Titration/Optimization (14 days, optimize settings to be 
used during treatment phase ) 
• Unblinded Treatment Phase (90 days)  
• Randomization to treatment withdrawal or continuation  
• 6-month open label follow up  
Outcome Measures  Primary outcome measure:  
o Trail Making test  
Secondary outcome measures include: 
• Measures of Cognition  
o Ruff 2 & 7  
• Physical Symptoms (self -report) 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 7 of 39 o Rivermead Post -Concussion Symptom Questionnaire (RPQ)  
• Psychological Health (Self -report) 
o Patient Health Questionnaire-9 (PHQ-9)  
o Columbia Suicide Severity Rating Scale (C -SSRS)  
• Quality of Life  
o Traumatic Brain Injury Quality o f Life (TBI-QoL subscales)  
• Measure of Global Function  
o Glasgow Outcome Scale – Extended (GOSE)  
Safety Endpoints  Rate of adverse events, serious adverse events and adverse device effects  
Statistical 
Methods and Sample Size Determination  This is a single center, feasibility study to be performed by a sponsor investigator at an academic institution.  All b aseline, procedural, and safety a nd effectiveness 
follow -up da ta will be  summ arized with a ppropria te descriptive  statistic s.  For 
continuous variables, w e will summar ize da ta by the mean, m edian, standar d 
deviation, minimum an d max imum.  F or non-c ontinuous v ariables we will 
summ arize by percentage s and frequenc y dist ributions.   We will ta bulate data for 
all enrolled pa tients. 
2. INTRODUCTION   
This study involves the treatment of cognitive impairment secondary to traumatic brain injury 
(TBI) using the Me dtronic  Percept PC for central th alamic  deep brain stimulation (CT-DBS).  
The proposed study , if successf ul, will p rovide supporting e vidence f or the development of a 
nove l therape utic approach utilizing CT-DBS to imp rove th ese enduring cog nitive  impairme nts 
arising  in per sons with multi -focal st ructural brain injuries.  This re search will add ress the cr itical 
gap of the l ack of any ava ilable treatm ents.  CT-DBS targe ts well-def ined neuronal popula tions 
within the  central thalamus th at have known ana tomica l and physiological specializations, which 
not only provide a key role in arousal regula tion during cog nitively-me diated behavior s, but also 
exhibit a par ticular vulne rability to dysfunction in the se tting of multi-foca l, non-sel ective brain 
injuries. 
The p roposed study builds on a pre vious c linical study of CT-DBS in subj ects with v ery sever e 
traumatic brain inju ries (Schiff et al. 2007 [ 22]; Giacino et al. 2012 [ 10]).  In the prelimin ary 
clinica l and pr eclini cal studies, we  have ide ntified tha t CT/DBS ac ts through sp ecific circuit and 
cellul ar mechanisms th at count er the effects of de afferenta tion and impai red cellul ar function 
across long-range cor tico- cor tical conn ections and modula tory cor tico-striato-pa llidal-
thalamocortical p athway s following bra in inju ries by direc t activation of the frontostriata l 
network.  We have fur ther identified a strategic location within the three-dimensiona l conf ines of 
the ce ntral thalamus th at provide s an optima l mea ns for f acilit ating ar ousal, a ttention, ex ecutive  
function a nd motiv ation. 
Our p roposed study a ims to suppor t developme nt of CT-DBS as a nove l therape utic avenue for 
accessi ng co gnitive  reserve in pa tients with acqui red brain injurie s.  In the proposed fea sibili ty 
study of 6 subjec ts at a single inve stigational site, we will te st the safety of CT-DBS in the 
moderate to sever e traumatic brain injury (SMTBI) population with GOS E 5-7 leve l recovery 
and collec t data to establish the translation of preclinica l studies into human appli cation of CT-
DBS.  We estimate a screen fail ure rate of 3:1 for this study.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 8 of 39 This is a single-site fea sibili ty study being conducted by a sponsor-inve stigator.  There have been 
no change s made to the  Medtronic Percept PC  for use in this stu dy. 
2.1. Traumatic Brain Injury 
TBI is a l eading cause of death and long-term dis ability in the  United State s as well as worldwide 
(Murray and Lopez 1997 [ 19]).  Sig nificant a ttention ha s been g iven to TBI in recent ye ars, 
particularly due to significant numbers of military per sonne l who have suffered TBI in comba t 
since 2000.  A ccording to the D efense and Vet erans Bra in Injury Center, there were 212,742 
TBIs between 2000-2011Q1 in a ll Armed Fo rces and 2,235 of these were sev ere TBI s.  
Additionally, the statistics of TBI are even more concerning in the  civilia n popul ation.   In 
addition to 50,000 TBI- related dea ths in the  US civilian population, ther e are over 1 million 
Americans treate d in emergency dep artments every year a nd 235,000 hospit al admissions 
(Corrigan e t al. 2010 [ 4]).  I t is estimated tha t 43%  of those discharged from ho spital admissions 
(124,000 pa tients pe r year) will d evelop long-t erm dis ability due to TBI (Sela ssie e t al. 2008 
[27]).  Th us, T BI disproportionately affects youn g and other wise healthy individuals who could 
contr ibute  to the wo rk for ce.  The  intervention proposed here is aimed at providing func tional 
improveme nts that may produce social and voca tional reentry an d imp roved vocation al 
performance .  Successful treatment of individuals in this disability range thus has the potential 
for tremendous impact, both for the individual and for society. 
Deep bra in stimulation is a standar d FDA approved t reatm ent for advanced moveme nt diso rders 
and holds great pr omise  for other neurolog ic disorders, inc luding TBI b ecause of it s distin ct 
mechanism of  action tha t can produce contr ol of axona l action potentia l generation.  The s afety 
and fea sibili ty of DBS for pa tients in  chronic post- traumatic injury who fulf illed the behaviora l 
criteria for the minimally consc ious st ate (MCS) and emergence fr om minim ally consc ious st ate 
(MCS and EM CS) has been demonst rated in a previous ID E and we have prov ided the  proof-of-
concept that cog nitively-mediated functions can be  facilit ated in chr onic brain inju ry with DB S 
directe d into the  cent ral thalamus (Schiff et al . 2007 [ 22]).  The  scient ific basis for the C T/DBS 
approac h taken here ha s evolved over a 20-year p eriod of s tudy of the pa thophysiology of 
impaired consciousne ss in h uman subj ects a nd the  physiolo gical inv estigations of the role of the 
centra l thalamus in fo rebrain ar ousal regulation (Purpur a and Schiff 1997 [ 20]; Sc hiff and P lum 
2000 [ 21]; Shirva lkar et al. 2006 [ 28]; Schiff et al. 2007 [ 22]; S mith e t al. 2009 [ 29]; Schiff 2008 
[23], 20 09 [24], 2010 [ 25], 2012 [ 26]).  These studie s are des cribed in more deta il in the s ection 
that follows.  
Approximately 70% of p ersons who susta in mod erate to severe TBI exper ience chr onic cog nitive  
impairme nts (TBI Mode l Systems N ationa l Data and Sta tistical Cent er [31]) that d is rupt 
vocationa l, social and emotiona l functioning.  This is due, in par t, to diffuse  axona l inju ry which 
results in wid espread disconnection acr oss the cerebrum, leading to secondary neurona l death 
concentrated in the intralaminar nuclei of the central thalamus.  A fter one y ear, one- third of the se 
individua ls remain unemployed a nd ne arly 40% continue to require super vision (TBI Mode l 
Systems N ational Data and Sta tistical Cent er [31]).  After five ye ars, more than 30% still require 
some leve l of sup ervised ca re, and 29% report diss atisfaction wi th life (Co rriga n 2014 [ 5]).  Self-
report and neuropsychometr ic findin gs sugge st that slowing  in processi ng speed, mental fatigue 
and deficie nt mental control contribute  significa ntly to re sidual disability following TBI.  We 
have e stablished tha t CT-DBS can significa ntly modul ate and fac ilitate performance acr oss a 
wide  range of ex ecutive  function tasks in the non-human pr imate (Baker e t al. 2011 [ 1]; 2012 
[2]) and in a  pilot huma n stu dy (Sc hiff et al.  2007 [ 22]), inc luding ta sks involving sustained 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 9 of 39 attention, working me mory and complex visua l pattern recognition.  We postulate based on our 
prior investigation that the effects of CT-DBS are mediated by activ ation of downregulated 
frontocent ral cortical regions and will produce improveme nts in p rocessi ng speed and ex ecutive  
functions a s measured by standar dized neuropsychometr ic measures (Trails B, continuous 
performance ta sks) and customized behaviora l tasks a ssayin g sust ained attention and working 
memory.  We also a nticipate that these change s in cog nitive  efficiency will facilita te 
improveme nts in vocation al produc tivity, psyc hologica l health and self- reported qua lity of life. 
2.2. Rationale for Proposed Study  
In the proposed f easibility  study of six subj ects, we  plan to eva luate the safety and eff icacy of 
CT/DBS in pa tient subj ects who have recove red from a modera te or sever e brain inju ry (initia l 
GCS 12 or low er) to an out come leve l ranging from GOS E 5 to the low er ha lf of GOSE 7.  A s 
briefly outlin ed be low and based on our pre-c linical studie s of C T/DBS in int act non- human 
primate s and rodents with and without TBI, and our c linical exper ience with C T/DBS in 
MCS/EMCS subj ects, we outline  the rationale that this n ew patient TBI popula tion is  optimally 
matche d to obtain c linica lly mea ningful benefits from C T/DBS (se e Figure 1).  We are targe ting 
a collec tion of  well-def ined neuronal populations within the central thalamus th at have known 
anatomical and phy siological sp ecializations that both provide a key role in arousal regulation 
during co gnitiv ely- mediated behaviors and are par ticularly vulne rable to dysfunction in the 
setting of multi - foca l, non-sel ective brain injuries.  
As per Figure 1, an optimal benefit of CT/DBS in patients recovering from moderate to severe 
traumatic brain injury is proposed for the functional outcomes cap tured across the GOSE level 5 
to 7 range on this scale.  The conceptual basis for targeting this population includes evidence that 
CT/DBS can have a significant behavioral facilitation effect across the range of minimally conscious state (Schiff et al. 200 7) to executive function in the intact mammalian forebrain 
(Baker et al. 2011, 2012, 2013).  Patients with initial moderate to severe brain injury (GCS< 12) 
and recovery to GOSE level 5 to lower 7 are anticipated to demonstrate significant cerebral deafferentation leading to a large population of neocortical, striatal and thalamic neurons that do 
not reach their full potential dynamic range as a result of deafferentation but could under 
conditions of sufficiently increased background synaptic activity. 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 10 of 39 Figure  1: Effects of CT/DBS are Present across the Continuum from MCS to Healthy Intact 
Brain  
 
2.3. Rationale for CT/DBS 
The fundamenta l ration ale for CT/DBS a s a therape utic moda lity in the SMTBI pa tient 
popula tion with recoverie s in the  range of GOS E 5-7 targeted her e is based on several 
consideration s:  
• the frequent observation of a specific clust ering of neuropsychologi cal imp airme nts in 
this p atient popula tion 
• the specific role of frontostriata l syste ms in e stablishing  these specific 
neuropsyc hologica l functions in the b rain 
• the func tional role of the central thalamu s in suppor ting frontostriata l systems and 
regula ting ac tivity across frontostriata l neurona l popul ations in response to cog nitive 
demands 
• the commo n pathology of deafferentation of the central thalamus ar ising across a ll 
moderate to severe brain inju ries with a  max imal predicted p reservation of neurona l 
cell types in the  GOS E 5-7 leve l recovery from STBI pa tient popul ation 
• clin ica l and pre -clinica l studi es demonst rating  that CT-DBS can facilit ate behavior s in 
humans and rode nts with T BI, and tha t these specific neuropsychologica l functions 
affected in the SMTBI pa tient popula tion can be  significa ntly facilitated by CT-DBS 
in a huma n subj ect with v ery severe bra in inju ry, as well as in int act non-human 
primate s. 

CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 11 of 39 2.4. Neuropsychological impairment following moderate to severe TBI: 
Target patient population  
Diffuse t raumatic brain injurie s produce a very wide  range of neuropsychologica l deficits th at 
associate with distin ct inju ry pa tterns but have c onsid erable overlap (Levin  et al. 2013).  Several 
studies, however , have char acterized common sy mptom clu sters whi ch do show cl ear 
consistency a cross large population cohor ts of patients with both moderate to sever e and mild 
traumatic brain injuries (Levin e t al. 2013 [ 14]; Dikm en et al. 2003 [ 6]).  A larger proportion of 
the STBI pa tient population t argeted her e is known to suffer signifi cant ongoing morbidity due to 
cognitive  impairme nt (D ikmen e t al. 2003 [ 6]).  A systema tic re lationship ha s been e stablish ed 
between the sev erity of initia l deafferentation ( as assessed  by c linica l variable s) and 
neuropsyc hological measure s of working memory, l earning, a ttention, and information 
processi ng speed ( Dikmen e t al. 2003 [ 6]).  Deta il ed eva luation of a cohort of 500 pa tients 
suffering STBI provide s additional population da ta suppor ting both the uniquene ss and the 
specificity of measures of working me mory, attention and pro cessi ng speed in the STBI pa tient 
popula tion t hat identify the sub-cohort we plan to t arget in this stu dy (Dikmen, unpublished 
studies).  Specifically, population data show clear separation of performance of the Trails B test 
(TMT-B) in the group of symptomatic patients with GOSE 5- 7 level recovery from those in the 
Upper Good recovery range (GOSE 8).  These population- based data show a mark ed difference 
in median completion time on the TMT-B between patients functioning in the Lower or Upper Moderate (UM=76s) to Lower Good (LG=75s) outcome categories of the GOSE, as compared to those functioning in the Upper Good (UG=52s) range.  A pr imacy of these symptoms in the  
STBI group is fur ther identified in studies of outcomes of mild T BI suppor ting the biological 
continuity of the e ffects of TBI and linkage of the pr imary neuropsychologi cal funct ions t argeted 
for suppor t here using CT-DBS.  In mild T BI subj ects, processi ng speed def icits ar e identified a s 
the fir st principal component of m easurable d
 eficits, followed by an index of visua l working 
memory (Levin e t al. 2013 [ 14]).   Th ese measurements are c onsist ent with the  hypothe sis th at the 
anterior forebrain is the area most se nsitive  to deaffe rentation inju ries associate d with TBI of a ll 
types (Schiff 2010 [ 25]).  
2.5. Role of frontostriatal systems in supporting sustained attention, 
working memory and processing speed 
Hum an neuroimaging and studie s in non-huma n primate provide a convergence of e vidence tha t 
frontostriatal systems organize and support the neurophysiological substrate underpinning a 
group of psychological capacities collectively described as executive functions (Stuss and Knight 
2013 [ 30]).  At the core of this wide -ranging set of capacities are the neuropsychological 
functions of sustaining attention; holding instructions or briefly presented information in 
memory; and processing in formation quickly ahead of executing a variety of motor responses 
such as gestures and spoken language.  Persistent activity in specialized neuronal populations in frontal cortex, striatum and thalamus has been consistently identified as supporting sustain ed 
attention, working memory, and processing speed (McCormick et al. 2003 [ 18]).  The loss of 
dynamic range of activation of frontostriatal systems in response to demands on executive function systems can thus be understood as the result of deafferentation of these neurons resulting from brain injuries and of their main source of activation in the central thalamus (see 
below).  The dominance of psychol ogical effects of STBI by the cluster of impaired  sustained 
attention, working me mory, and cog nitive  proce ssing speed d eficits is the direct result of the 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 12 of 39 graded imp act in those pa tients re maining func tionally affected by their injuries of the loss of this 
gene ral purpose base function of frontostriata l syste ms (Dunca n and Owen 2003 [ 7]). 
2.6. Role of central thalamus in pathophysiology of moderate to severe 
TBI 
The centra l thalamus is anatomica lly specialized to provide strong syna ptic drive across the 
fronta l and prefrontal cortices and r ostral striatum in response to cog nitive  demands (re viewed in 
Schiff 2008 [ 23]; Ma ir and Hembrook 2012 [ 16]).  Control of the activ ation of centr al thalamus 
in response to these demands emanates fr om m edial front al cortex a nd is  modulated by the f ull 
set of bra instem ‘arousa l syste m’ inputs from c holin ergic, nora drenergic, and other monoa mine  
pathways.  Di ffuse ax onal inju ry results in wid espread disc onnection acr oss the cerebrum with 
secondary neurona l death of these ce ntral thalamic neurons arising a s a common path ology; the 
concentration of damage in the central thalamus (intralaminar) and re lated association nucle i 
indexe s the sever ity of out come (Maxwe ll et al. 2006 [ 17]).   Th ese nuclei show a greater 
vulne rability to multifo cal b rain injury because of the ir widespread pr ojections th at lead to th eir 
dispropor tionate deafferentation th at is a ssociated with di ffuse  injuries.  Loss of input fr om th ese 
neurons s econdary to this d eafferentation l eads to a fa ilure to m aintain su fficie nt membra ne 
depol arization to produce or sustain action pote ntial firing ra tes typical of frontocor tical and 
striatal neuronal populations in the wakef ul state; in studie s of severely bra in inju red human 
subjects who re main within the very severely impaired ca tegorie s of minimally conscious sta te 
and conf usiona l state this effect ca n be measured in diff erences in region al cereb ral metabolic 
rates (Fridman e t al. 2014 [ 9]); the level of recovery of ce ntral thalamic meta bolism in th ese 
studie s grades level of r ecovered behaviora l function. Severa l circuit- leve l specializations of the 
centra l thalamus under lie dysfunction of the forebra in after STBI and d eafferenta tion of  the 
centra l thalamus (Sc hiff 2010 [ 25]). 
3. Study Objectives   
This is a feasibility study to infor m the  safety and eff icacy of centra l thalamic-deep brain 
stimulation (CT-DBS) in the  treatment of chr onic cognitive  impairment and re sidua l disability 
caused by trauma tic bra in injury (TBI). 
4. Study Design  
This is a single arm, sponsor -investigator feasibility study to be conducted at a single 
investigational site.  
5. Study Device 
This study utilizes the Medtronic Percept PC Deep Brain Stimulation system. The Percept PC 
has been approved by the FDA for B ilateral stimul ation of the inter nal globus pa llidus (GP i) or 
the subthala mic nucleus (S TN) as an adjunc tive therapy in re ducing some of the sy mptoms of 
advanced, levodopa- responsive Parkinson's dis ease that are not adequately contr olled with 
medi cation.  The device is being provided by the manufacturer, Medtronic, and no changes have 
been made to the device for use in this study. 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 13 of 39 The Percept  PC s ystem consists of  the neur ostimul ator, leads, extensions and c linician and 
patient progra mmers. As shown in Figure 2 be low, there are separa te progra mmers for the  
clinician and the patient.    
Figure  2: Percept PC S ystem  
 
 
6. STUDY PLAN 
The research plan is organized ar ound the central a im of acquiring pilot c linica l data that will 
inform the  safety and eff icacy of centra l thalamic-deep bra in stimulation (CT-DBS) in the 
treatm ent of chronic cog nitive  impairment and re sidua l disability caused by TBI.  We intend to 
recruit 6 a dults w ith a histo ry of moderate to severe TBI (GCS = 3-12) who continue to 
demonst rate neuropsyc hological impairme nt and func tional disability at least 24 months post-
injury ( Glasgow Ou tcome Scale- Extended = 5-7) {W ilson, 1998, Struc tured interviews for the 
Glasgow Out come S cale and the extended Glasgo w Out come S cale: guide lines for their use}.   
Fol lowing study enrollment, par ticipants will be  randomly a ssigned to 1 of 3 base line condition s 
lasting  30, 44, or 58 days.  Two par ticipants will be  assigned per condition.  The staggered 
baseline s chedule will enable a ssessment of CT-DBS effec ts within individu al subj ects and 
across subj ect pairs.  Eac h participant will also be  randomly a ssigned to a t reatm ent with drawal 
or continuation condition.  This process is explained in detail in Section  6.3 of this document. 
Following  a 30 to 60-day pre surgical baseline phase to ensure surgical readin ess and e stablish 
curre nt level of function a cross multiple  doma ins, p articipants will und ergo impla ntation of a 
deep bra in stimulator in the  central lateral nucleu s of the th alamus.  Implantation of the 
stimula tor will be  followed by a staggered po st-surgica l baseline that will in crease prog ressively 
for each pa ir of par ticipants.  After a 14-day stimul ation t itration phase, CT-DBS will be  

CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 14 of 39 admi nistered for 90 c onsecutive days.  F ollowing  the unblinded stimulation phase, p articipants 
will enter a 21-day double-blinded t reatment withd rawal phase.  The study will formally 
conclude at the end of the withdrawal phase.  Participants will be given the option to continue to 
use the device following study termination, if they are receiving benefit. 
The study de sign inc ludes 3 unique featu res that were incorporated to detec t treatm ent eff ects, 
reduce sour ces of bia s and estimate generalizability: 
• Subject p airs will be  randomize d to one  of 3 progre ssively-in creasing baseline 
observation per iods.  Should t reatment be e ffective, imp roveme nts in perf ormanc e on 
the outc ome measures will o ccur in tempora l contiguity to the onse t of CT-DBS .  
This d esign elemen t will h elp di fferentiate the effects of CT-DBS from random 
fluctuations in function. 
• Treatme nt will be  withd rawn in a double-blinded manner - neither the inves tigators 
nor the subj ects will h ave knowledge of when CT-DBS is dis continued.  This featu re 
will minimize the influence of exa miner and subj ect bias on the outcome s of interest. 
• Ou t come a ssessment acr oss multiple  subj ects following establishme nt of a stable 
baseline will enable identifi cation of a signifi cant t reatme nt effect and per mit 
inferences to be dra wn concer ning gen eralizability  of results (Schi ff, 2007 [ 22], 
Behaviora l imp rovemen ts with th alamic stimulation af ter severe t raumatic brain 
injury). 
Study Operations :  This is a single site study.  All procedures, assessments and follow -up care 
will be take place at Stanford University under the leadership of Jaimie Henderson, MD.  The 
study co- investigators from Weill -Cornell, Spaulding Rehabilitation/Harvard, Cleveland Clinic 
and University of Utah will travel to Stanford for procedures.  Two additional Weill- Cornell 
faculty members will travel to Stanford to do EEG testing and other data collection.  Dr. Nicholas Schiff at Weill -Cornell will lead the data analysis.  
The members of the team have had successful remote collaborations for over a decade.  The 
project has adequate funding for remote collaboration tools for conference calling and document 
sharing, travel for in -person meetings and a project manager.   
6.1. Study Population  
6.1.1. Inclusion Criteria  
• History of moderate to severe TBI based on worst GCS score within first 48 hours of 
injury (acceptable GCS range = 3-12) 
• Age 22-60 
• At least 24 months from date of onset  
• Fluent in English and able to independently provide consent  
• Retains decision -making capacity and is able to function independently (i.e., 
unsupervised) in the home setting 
• Multiple unsuccessful attempts to sustain competitive employment or complete an 
academic degree-granting program of study 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 15 of 39 • Either receives no CNS stimulants or other medications known to affect cognitive 
function, or on stable doses of these medications for the last three months (see 
additional information regarding concomitant medications below)  
6.1.2. Exclusion Criteria  
• History of major developmental, neurologic, psychiatric or substance use disorder 
with evidence of disability prior to onset of TBI 
• Major medical co -morbidities  including: end stage renal failure, severe heart failure, 
severe congestive heart disease, coagulopathy severe r espiratory problems, severe 
liver failure, uncontrolled hypertension or other significant medical co morbidities  
• Have had a documented seizure within 3 months of study screening (subjects may re -
screen if seizure free after initial screen failure  
• Malignancy wi th < 5 years life expectancy  
• Untreated / uncontrolled (severe at the time of enrollment) depressio n or other 
psychiatric disorder  
• Women of childbearing age who do not regularly use an accepted contraceptive method   
• Inability to stop anticoagulation or platelet anti -aggregation therapy before, during 
and after surgery  
• Previous DBS or other brain implants  
• Previous ablative intracranial surgery  
• Implantable hardware not compatible with MRI  
• Condition requiring diathermy after DBS implantat ion 
• Hardware, lesions or other factors limiting placement of electrodes in optimal target location in the judgment of the operating surgeon 
• Concurrent enrollment in any other clinical trial  
• Any condition or finding  that, in the judgment of the PI, signific antly increases risk or 
significantly reduces the likelihood of benefit from DBS  
6.1.3. Concomitant Medications  
Subjects who are on centrally -acting medications will remain eligible for enrollment as long as 
the dose of the medication has been stable for at least  three months prior to the date of 
enrollment.  All concomitant medication and concurrent therapies will be documented during the Baseline Visit, and at every subsequent study visit.  At each study visit, the Study Coordinator will review and print the list of concomitant medications that were completed at the participant’s 
prior visit in order to accurately review and document changes in the participant’s concomitant 
medications or concurrent therapies.  The generic name of the drug, presence/absence of th e drug 
at the time of randomization, date started, dose, route, unit frequency of administration (i.e., 
schedule) and the date stopped or changed will be recorded.  We will also record whether the 
medication was prescribed to treat an AE (and, if so, the date of the AE form) or a new clinical 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 16 of 39 problem that arose after enrollment.  The same information will be recorded for non -
pharmacologic therapies, with the exception of dose and route of administration.  
If there are any changes in a centrally -acting medication, or if a new centrally -acting medication 
is added following randomization, the Study Coordinator will apprise the Sponsor and a protocol 
violation will be recorded.  The Sponsor will evaluate the potential influence of the new medication on the study treatment and will make a disposition regarding continued participation 
in the trial.  Any disposition recommending withdrawal from the trial will be reviewed by the 
Clinical Oversight Committee (see Section  10 below) before any action is taken.  
6.2. Informed Consent  
If no exclusion cr iteria are ide ntified during the p re-screening interview, the 
investigator/coordina tor will provide the informed consent form ahead of time to potential 
candidates.  Candidates will be asked to review and mark the document with questions.  Study investigators will be available for questions in person or over the phone or teleconference.  The 
coordinator will then  arrange for a consent mee ting with the sponsor to: (a) review the in formed 
consent for m; (b) cl early explain a ll stu dy proce dures, risks, pot entia l benefits, a lternative 
therapies (if ava ilable); and (c) answer any questions the par ticipant may have reg arding the 
study.  The sponsor will be present for the entire informed consent meeting.  A conse nt for 
release of medi cal recor ds will be  obtained during the consent m eeting to acquire additiona l 
informa tion and medi cal records related to stu dy eligibility.  The  participant will be  remind ed 
that study elig ibility will not be f inalized until a ll screening a nd pre-ope rative  tests and 
procedure s have been 
completed. 
After the study has been fully explained to the potential subject and all questions have been a
ddressed, written informed consent will be obtained prior to the performance of any study-
specific procedures.  The method of obtaining and documenting the informed consent and the 
contents of the consent will comply with ICH- GCP and all applicable regulatory requirements, 
including local IRB requirements.  
6.3. Randomization to Multiple Baseline Condition and Treatment 
Withdrawal  
Following study enrollment, par ticipants will be  randomly a ssigned to 1 of 3 base line condition s 
lasting  30, 44, or 58 days.  Two p articipants will be  assigned per condition.  The  staggered 
baseline s chedule will enable a ssessment of CT-DBS effec ts within individu al subj ects and 
across subj ect pairs.  Eac h participant will also be  randomly a ssigned to a t reatm ent with drawal 
or continuation condition.  Ne ither the inve stigator nor the par ticipant will h ave knowledge or be 
apprised as to wh ether DBS is on or off durin g this p eriod.  For par ticipants assigned to the  
treatm ent withdrawal condition, DBS will be  switched off for 21 day s (on days 170, 184, and 
198 for cohor ts 1-3, re spectively) immediately after compl eting the 90-day unblinde d treatm ent 
phase.  P articipants ra ndomi zed to the  continuation c ondition will continue to re ceive stimulation 
12 hour s per d ay over the same 21-day period.  Upon conclusion of the 21-day t reatm ent 
withd rawal phase, par ticipants will und ergo a f inal re- a ssessment on the multi- dimension al 
outcome a ssessment ba ttery and on th e electrophysiolog ic measures (on day 191, 205, or 219, 
depending on cohort).  Currently there are no known safety issues related to withdrawing 
stimulation.  The purpose of this f ollow -up visit is to det ermine  if there is evidence of loss of 
effect in those  assigned to the t reatment withd rawa l condition, and to eva luate the influence of 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 17 of 39 intervening fac tors on the effectiveness of DBS.  The  trial will be  cons idered comple te at the end 
of the t reatme nt withd rawal phase. 
6.4. Screening Imaging  
Following study enrollment but before the screening visit, participants will undergo volumetric 
MRI imaging including diffusion tensor imaging for surgical planning and to assess the degree of structural damage, which could preclude successful targeting of the DBS leads.  Feasibility of 
successful targeting of the CT will be determined by the investigative team.  If targeting is 
determined to be infeasible the subject will be withdrawn from the study.  
6.5. Screening and Preoperative Baseline Evaluation 
One to two months bef ore DBS implant surgery (with 1 month def ined as 30 day s ± 3 days), 
participants will compl ete physical and neurologi cal screening exa minations and complete 
labora tory studies to en sure study eligibility and suit ability for surgery.  A screen failure is 
defined as a potential participant who has been consented for screening but is not enrolled for randomization and implantation.  A screen failure does not meet all inclusion criteria and/or has answered or tested affirmatively to any excl usion criteria.  A potential participant may also fail 
screening if they are deemed unsuitable for participation based on the clinical judgment of the sponsor investigator.  We estimate the screen failure rate to be 3:1, which is based on efficiently pre-s creening interested participants, and extensive team review of each case prior to screening.  
Participants will also under go pre-operative  multi- dim ension al baseline asse ssment using a 
battery of cog nitive  (e.g., a ttention, m emory, information proce ssing speed, ex ecutive  functions), 
psychological health (e.g., dep ression, anxiety) func tional status (e.g., e mployme nt level) and 
quality of life (e.g., sa tisfaction with life ) measures (see Description of Outcome Asssessments 
below).  A st ructured interview will also be conducted to obtain additiona l background 
information and det ermine  pre-injury leve ls of acade mic, vo cation al and social function.  These 
evaluations can be done either on a single day or on multiple days. 
6.6. Inpatient Hospital Stay  
Following completion of the pre opera tive base line evaluation, par ticipants will be  admitted for 
surgica l implanta tion of the  DBS sy stem.  All  patients will re ceive one DBS l ead in each side 
of the dien cephalon.  Both l eads will be connected to a single pulse genera tor th at may be 
impla nted on the right or left side o f the chest.  The procedur es may be performed on the 
same day  or staged .  The su rgica l procedure s are discussed in mo re deta il below. 
6.6.1. Stage I:  Bilateral DBS Lead Implantation  
Patients will undergo implantation in a fashion similar to that routinely performed by the investigators for movement disorders (Bronte -Stewart, Louie, Bat ya, & Henderson, 2010 [ 3]; 
Machado et al., 2006 [ 15]).  We anticipate that targeting will be simpler in the present study than 
in our prior experience (Schiff et al., 2007 [ 22]) because patients in the present population are 
expected to have less post - traumatic gross anatomical deformities of the cerebrum and 
diencephalon (see Figure  3).  Surgical planning will be performed prior to surgery based on 
preoperative volumetric MR images acquired with and without contrast, unless there is a clinical contraindication to the use of contrast ( Figure 4 below).  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 18 of 39 Figure  3: Bilateral DBS,  targeting the ce ntral thal amic region.  In this example, the DBS l ead 
has 1.5 mm height contacts, separated by 1 .5 mm gaps.  The ventr al-most co ntact 
was ta rgeted at the central lateral nucleus of the thalamu s. 
  
 
Figure  4: Th alamic nuclei visualized at 7T (left), with corr esponding segme ntations (right) 
based on the Mor el thalam ic atlas (T ourdias, Saranathan, Lev esque, Su, & R utt, 
2013  [32])).  The central lateral nucleus is highlighted in orange.  
 
One or mor e days pr ior to surgery, f ive st ainless steel fiducial m arkers will be implanted in the 
skull through small stab incisions under local ane sthesia in the neurosurgery outpa tient c linic 

CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 19 of 39 (Holloway et a l. 2005 [ 12]).   A high- resolution volumetr ic CT s can will be obta ined and these 
images will be impo rted into the surgical plan ning station and fuse d with  the pre vious ly 
obtained MRI image s, and the f inal target location  deter mined.  On the day of surgery, the 
patient will be positioned in a custom head c radle.  The patient’s anatomy will be registered to 
the neuronavigational system by touching each fiducial marker  with a passive pl anar 
registration  probe equipped with reflective  sphere s, which can be t racked by the came ras of the 
surgica l naviga tion unit.  Entry points will be  marked on the s calp an d the  patient will be 
prepared a nd draped in  a sterile fa shion.  Afte r burr-hole pla cement, high- impact plastic tow ers 
will be attached to the skull bilaterally with  3 titanium bone scre ws.  A st erile ref e rence arc will 
be fa stened to  the base of the platfor m to allow real- time tracking for maximum accuracy.   Each 
fiducial m arker will  be touched through the dra pe to p erform reg istration again.  Alignment of 
the trajectory will be accomplish ed by adjusting th e framele ss device platform to orient the 
trajectory to the planned t arget, using  the guidance vie w of the targe t provided by the planning 
software. 
Im planta tion will be  guided either by intraoperative imaging (O -arm or MRI) or by 
microelectr ode recording and int raopera tive macrostimulation via the DBS l eads.  Image -guided 
procedures will be performed under general anesthesia. Microelectrode-guided procedures will 
be performed under conscious sedation, titrated according to the judgement of the anesthesiology 
team. In either case, routine procedures for DBS plac ement will be used. In a recent meta-
analysis, no significant difference was found between the two techniques with regard to targeting 
accuracy and symptom reduction (Ho et al. Mov Disord 2017). Based on the results from the first 
5 patients in this study,  there does not appear to be a unique neurophysiological signal associated 
with the CL nucleus. In addition, intraoperative stimulation has not caused side effects that 
proved informative with relation to the eventual postoperative lead location. Therefore , the final 
patient in the study will be implanted using image guidance, which we believe will result in equivalent or improved accuracy. 
On
ce the f inal location for the DBS l ead is sel ected, it will be  anchore d to the skull in the  routine 
fashion and the su rgica l site s close d under seda tion.  The  procedure will th en be repeated on the 
opposite side .  Following surgery, the  patient will be  admitted for obs ervation under routine 
neuro surgica l care fo r intracrania l surgery.  The inv estigators will attempt to implant both side s 
in the sa me surgica l procedure.  Ho wever , if the pa tient is tire d or, if in the opinion of the 
investigators there is added risk to c ompl eting the impla ntation of the s econd side in the  same 
day, the investigator ca n make the dec ision to stop the surgery and implant the s econd side in a 
separa te date, no more than 60 day s after implantation of the fir st sid e.  Be cause this is  routinely 
done in surgery for movement disorder s we will not con sider staging  of the DBS l ead impla nts to 
be a deviation of the pr otocol.  At l east one C T scan will be done postopera tively dur ing the 
hospita l admission to v erify lead lo cation and rule out intr acranial hemorrhage. 
6.6.2. S tage II 
Implanta ble pulse generator (IPG) implantation and connection to  the DBS l eads.  This is a 
routine proce dure that will be  performed under gen eral ane sthesia on  the sa me day, following 
bilateral DBS l ead implant.  The pulse gene rator (Mode l 37601 PC , Medtronic, Inc., 
Minneapolis, MN) will be  impla nted on the  right or l eft che st and connected to the DBS l eads.  
Under genera l ane sthesia and with standar d surgica l technique for DBS, the skin over the dista l 
tip of the l eads (protected by a te mporary conn ector) will be  opened and the connector  
externalized and dis carded.  An  approx imately 7-10 c m incision will be  made in the 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 20 of 39 infraclavicular region and a pocke t fashioned for the pulse gene rator.  A tu nneling tool will be 
used to cr eate a subcutaneous tunne l connecting the infraclavicular subcutaneous pocke t to the 
scalp in cision wh ere the l ead is ext ernalized.  The  exte nsion wi res will be  passed with the 
tunne ling tool.  The  extension wi res will th en be connected to the DBS l eads and to the pulse 
generator.  Medical adhesive may be used to insure a tight seal and improve signal quality. The  
incisions will th en be a pproximated with st andar d surgi cal technique. 
6.7. Post-Surgical Washout Phase  
Participants will enter the washout phas e following hospital discharge.  The length of the 
baseline will be staggered for each participant pair.  The purpose of this phase is twofold: (1) to 
provide a 30-day surgical washout for resolution of any transient physiological or behavioral 
effects of surgery  and (2) to detect the temporal onset of the stimulation effects for each subject, 
should these occur at the time of stimulation titration onset.  At the end of the surgical washout 
period, the multidimensional outcome assessment battery that was administered during the pre-
surgica l baseline phase will be repeated to assess for any  changes in function before CT- DBS is 
switched on (see Description of Outcome Assessments below).  A CT scan will be performed on 
day 65 to assess the final lead location, after any post- surgical changes h ave been allowed to 
resolve.   
6.8. DBS Stimulation Titration/Optimization 
On completion of the postsurgical washout phase (beginning day 66, 80, or 94, depending on cohort), DBS will be turned on for the first time to initiate the stimulation titration phase.   During 
this phase, which will last 14 days for all participants, an array of stimulation parameters will be 
assessed to optimize the settings that will be used during the treatment phase.  See  Appendix 1 to 
this protocol for the  device pro gramming SOP.   
6.9. Unblinded Treatment Phase 
After DBS titration/optimization is complete, participants will enter the unblinded 90 -day 
treatment phase during which DBS will remain on for 12 hours per day.  At the end of the 90-day 
treatment phase, participants will undergo re -assessment on the multi -dimensional outcome 
assessment battery.  Electrophysiologic measures will also be sampled on day 139 (± 3 days), 
153 ( ± 3 days) , or 167 ( ± 3 days) , respectively, to compare performance before and after 
treatment.  
6.10. DBS S timulation Long- term Continuation  
If ongoing benefits for the subject are determined by the patient and the team, the patient will 
continue long- term DBS.  Decisions about the presence of benefit are expected to be guided by 
evidence of causal influence of DBS on changes in neuropsychologica l functions that covary 
with clinically meaningful outcomes on performance measures or quality of life indices.   After 
the in itial battery expires, a rechargeable replacement will be available for individuals who will 
continue with stimulation.  
6.11. Six Month Open Label Follow -Up Period 
There will be a 6- month follow -up period at the end of the unbli nded treatment phase.  There 
will be two visits during this period with the visits occurring at month s three and six.  The month 
three follow up visit will be to assess general health, quality of life and to monitor battery supply 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 21 of 39 of the device.  The six month follow up visit will be to assess general health, quality of life, 
neuropsychological status and to monitor battery supply of the device. 
6.12. Unscheduled Visits:  
Participants may have visits in between their regularly scheduled study visits if the sponsor -
investigator deems necessary.    
7. DESCRIPTION OF OUTCOME ASSESSMENTS  
7.1. Measures of Cognition  
• Trail Making Test (Primary Outcome Measure) {Army Individual Test Battery, 
1944, Manual of directions and scoring} .  The TMT is a measure of attention, speed, 
and mental flexibility.  It also tests spatial organization, visual pursuits, recall, and recognition.  Part A requires the individual to draw lines to connect 25 encircled numbers distributed on a page.  Part A tests visual scanning, numeric sequencing, and 
visuomotor speed.  Part B is similar except the person must alternate between 
numbers and letters and is believed to be more difficult and takes longer to complete.  
Part B tests cognitive demands including visual motor and visual spatial abilities and 
mental flexibility.  Both sections are t imed and the score represents the amount of 
time required to complete the task.  
• Ruff 2  
& 7 (Ruff, 1992, T he Ruff 2 a nd 7 Selec tive Attention T est:  a 
neuropsyc hologica l application).  The Ruff 2 & 7 Te st wa s developed to m easure 
two aspects of  visua l attention: sust ained attention (ability to maintain c onsist ent 
performance level over time) and sel ective attention (a bility to select relevant stimuli 
while  ignor ing distractors).  Th e test consists of  a series of 20 trials of a visual search 
and can cellation task.  The respondent det ects and m arks through a ll occurrences of 
the two target digits: “2″ and “7.”  I n the  10 Automa tic Detection trial s, the  targe t 
digits ar e embedded a mong alphabe tical letters that serve as dist ractors.  In the 10 
Controlled S earch tria ls, the  targe t digits ar e embedded a mong  other number s that 
serve as dist ractors.  Cor rect hits a nd error s are counted for e ach tria l and serve as the 
basis for scoring the te st.  Speed score s  reflect the total number of corr ectly ide ntified 
target s (hits).  Accuracy sco res eva luate the number of targe ts identified in relation to 
the number of possible targe ts. 
7.2. Physical Symptoms (self- report)  
 
• Riverm ead Post -Conc ussion Sy mptom Qu estionn aire (RPQ) {King, 1995, The 
Rivermead Post Conc ussion Sy mptoms Qu estionn aire: a  mea sure of sy mptoms 
commonly exp erien ced after h ead injury and its re liability} .  The  Rivermead PC S 
Questionnair e (RPQ) was originally developed a s a mea sure of sever ity of symptoms 
following mild T BI.  It c onsists of  16 post-concussion sy mptoms including  
headache s, dizziness, nausea/vomitin g, noise se nsitivi ty, slee p distu rbance, fa tigue, 
irritability, feeling depre ssed/te arful, feeling fr ustrated/ imp atient, forgetf ulness, poor 
concentration, taking longer to think, blurred v ision, light sensitivity, do uble vision 
and re stlessness.  In the o riginal version of the RP Q, participants ar e asked to ra te the 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 22 of 39 degre e (on a scale of 0 to 4) to whic h a particular sym ptom h as been abse nt or a mild, 
moderate  or severe problem ove r the previous 24 hour s compared with pre morbid 
levels. 
7.3. Psychological Health (self- report)   
• P atient Health Questionnaire -9 (PHQ -9) {Kroenke, 2001, The PHQ-9} .  The 
Participant Health Questionnaire 9 is a standardized assessment instrument designed 
to screen, diagnose, monitor, and measure the severity of depression. 
• Columbia Suicide Severity Rating Scale (C -SSR S) {Posner, 2011, The Columbia-
Suicide Severity Rating Scale: initial validity and internal consistency findings 
from three multisite studies with adolescen ts and adults} .  The C -SSRS is a 
standardized assessment instrument designed to assess the presence and severity of 
suicidal ideation and behavior, identify those at risk, and track response to treatment.  
It has three main sections that evaluate suicidal ideation, the intensity of ideation and 
suicidal behavior.  The first section, suicidal ideation, assesses risk ranging from a death wish or unspecific suicidal thoughts to active ideation with specific plans.  In 
the second section the severity of ideation is evaluated and takes into account the 
frequency, duration and controllability of suicidal thoughts as well as environmental and cultural deterrents and reasons for suicidal ideation.  The third section evaluates 
actual suicidal behavior and asks if there was an actual attempt, interrupted attempt, 
aborted attempt or preparatory acts of behavior.  It also asks whether there was active 
suicidal behavior at the time of assessment and, finally, if suicide was completed.  A 
fourth section is only answered in case there was / were suicidal attempts and 
measures the lethality and potential lethality of each suicidal attempt and respective dates.  The CCSRS is a widely -used instrument and is currently being utilized in 
other first- in-man DBS clinical trials.  The C -SSRS will be administered during the 
pre-surgery baseline assessment and then at any follow -up visit only if the 
participant screens positive for suicidal ideation/behavior on the PHQ -9 (i.e. 
score ≥  1 on question 9). 
7.4. Quality of Life (self- report)  
• Traumatic Brain Injury Quality of Life (TBI -QOL) {Tulsky, 2015, TBI- QOL: 
Development and Calibration of Item Banks to Measure Patient Reported 
Outcomes Following Traumatic Brain Injury} .  The TBI -QOL was developed as a 
comprehensive patient -reported outcomes (PRO) measurement system specifically 
for individuals with TBI .  It consists of 20 independent calibrated item banks and 2 
uncalibrated scales that measure physical,  emotional, cognitive, and social aspects of 
health -related quality of life.  We will administer the short form (6 -10 questions each) 
of the TBI-QOL Fatigue, Attention/Concentration, and Executive Function subscales. 
7.5. Global Functional Outcome Measure 
• Glasgow Outcome Scale – Extended (GOSE) {Wilson, 1998, Structured 
interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome 
Scale: guidelines for their use}.  The Glasgow Outcome Scale Extended (GOSE) is 
a measure of disability and handicap  intended for use following head injury.  The 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 23 of 39 GOSE subdivides the upper three categories of the original Glasgow Outcome Scale 
(GOS), severe disability, moderate disability and good recovery, into an eight-category scale: dead, vegetative state, lower seve re disability, upper severe disability, 
lower moderate disability, upper moderate disability, lower good recovery, and upper good recovery to provide more detailed assessment of the functional effects of the injury.  A structured interview has been developed to standardize assignment of an 
outcome category (Wilson et al. 1998). 
7.6. Participant Interview  
• A structured interview will be  administered to obta in information about pre injury 
medica l and socia l histo ry, and leve l of social, edu cation al and vocation al function. 
7.7. Exploratory Measures  
7.7.1. Electrophysiological 
Each enrolled participant will have electroencephalogram (EEG) studies obtained several times during the course of the study following DBS implantation.  The initial EEG recording will be 
made on the day of admission for surgery.  EEG recordings will be obtained using an EGI 
system (129 scalp sites using the Geodesic EEG Net Station (EGI, Eugene, OR) with the 129-
channel Geodesic Sensor Net (Tucker 1993 [ 33]).  For each recording session 5 minutes of 
resting baseline will be obtained at the beginning and end of the session.  In addition, subjects 
will perform the Attention Network Test paradigm, a standard measure for assessment of 
attention that has been normed in the study population (Fan et al. 2002 [ 8]).  T he ANT will be 
presented using Eprime (Psychology Software Tools) on a standard flat screen monitor and the 
total duration of each ANT experimental session will be approximately 25 min. Local thalamic 
recordings will be recorded using the Per cept PC system during the performance of the Attention 
Network Task.   
To measure local population dynamics within the central thalamus during stimulation conditions 
in clinic we will record a differential signal on pairs of open channels adjacent to the c hannel 
used for stimulation using the Percept  PC system. We will record up to 6 channels during OFF 
stimulation periods and 2 channels during stimulation. We will use a sampling rate of 250Hz (to optimize recording against known noise characteristics of the device) and filtered (4Hz to 
100Hz) in compressed format. To characterize the EEG activation profiles we will use monopolar and bipolar stimulation through each contact individually and pairs of contacts in 
ON/OFF blocks of 5 -10 second stimulation periods interleaved to obtain a minimum of 100 
seconds of recording per condition with matched adjacent resting periods.  
A similar approach will be used to collect behavioral, EEG and local thalamic recording data 
during performance of the Attention Network Task (Fan et al. 2002). EEG and local thalamic 
recordings will be synchronized using brief 1-2 second 20Hz pulses at the start and end of recording sessions.  We will compare behavioral and EEG effects during interleaved blocks of 
10 minutes of continuous ANT performance.  Monopolar review for side effects will be 
completed prior to behavioral testing with the ANT.  
We will use the sensing recording capabilities of the Percept  PC to obtain longitudinal samples 
of brain activity during sleep- wake cycles in betw een outpatient office visits. Recordings with 
the device will occur as described above and as follows. Uniformly sampled and bandpassed 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 24 of 39 power will be obtained from one channel per electrode every ten minutes over 2 months. These 
data are stored on the device and will be downloaded at patient visits during the trial.  We will evaluate the time domain recordings with spectral analysis.  
8. EARLY WITHDRAWAL OR TERMINATION  
Subjects will be informed that they may withdraw or be discontinued (early termination) from 
this study at any time.  Further, they will be informed that the Investigator may withdraw them if 
they fail to comply with the study requirements or if the investigator feels it is in the best interest 
of the subject to discontinue their participation.  The reason(s) for withdrawal or early 
termination will be documented on the appropriate page of the CRF.  No further study 
assessments will be performed after the subject has withdrawn.  
Subjects who consent to participate but do not receive the DBS device will not count towards the 
6 patients limit for this study and new patients will be screened.  No attempt will be made to 
replace subjects who are withdrawn or prematurely discontinue their study participation after the 
device has been implanted.  
9. ADVERSE EVENTS  
9.1. Adverse Event Identification and Assessment  
An adverse event is any undesirable clinical occurrence in a participant during the clinical investigation, having been absent at baseline (or, if present at baseline, appears to worsen), 
whether or not it is considered to be related to the device or to stimulation.  The investigator will 
not be required to record transient stimulation -induced neurological effects (e.g., paresthesias) or 
findings within normal expected postoperative outcomes.  For example, p ostoperative pain that is 
not outside expected levels will not be recorded as an adverse event.   Postoperative events that 
involve a clinically significant severity of symptoms, duration of symptoms, or that require deviation from usual postoperative clinical interventions (e.g., pain lasting longer than expected 
and requiring long-term opioid use) will be recorded as adverse events.  The testing of DBS in 
MCS subjects did not identify any adverse events that are specific to brain injured subjects.   
 
9.2.  Adve rse Device Effect  
An adverse device effect is a device related adverse event.   During this clinical investigation an 
event should be considered related to the device when it is the result of:  
• The implanted components (lead, extension, neurostimulator) 
• The implant procedure  
• Programming  
• Stimulation  
A non- related event is one that results from:  
• A patient related condition  
• Concomitant medication  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 25 of 39 • Other (specify)  
The relationship or association of the AE to the study product will be characterized by the 
Investigator as one of the following in Table  2.  
Table  2: AE Relationship to Device 
Relationship Definition 
Not related  There is no temporal relationship between the study product/treatment and the 
event, which makes a causal relationship clearly and incontrovertibly due to extraneous causes, i.e. not related to the study product.  
Unlikely  Other factors, such as concurrent illness, progression or expression of a disease, or a reaction to a concomitant medication are more likely the cause of the event .  
It is improbable that the study product/treatment caused the AE.  
Possibly  The AE cannot be fully explained by other causes, and it is possible that the study product/treatment caused the event.  
Probably  A reasonable temporal association exists between the AE and the study product/treatment, and, based upon the investigator's clinical experience, the association of the AE with the study product/treatment seems probable.  
Definitely A definite or certain temporal association exists between the AE and the study product/treatment, and, based upon the investigator's clinical experience, the association of the AE with the study product/treatment seems definite or certain.  
9.3.   Serious Adverse Events (SAEs)  
A serious adverse event is one that meets any of the following criteria (ICH Good Clinical 
Practice Guideline, April 1996, Section 1.50): 
• Results in  death  
• Is life threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
Events that do not meet these criteria are considered non-serious 
A planned hospitalization for pre-existing condition, or a procedure required by the Clinical 
Investigation Plan, without a serious deterioration in health, is not considered to be a serious 
adverse event.  
9.4. Anticipated & Unanticipate d (UADEs) Adverse Device Effects  
9.4.1. Anticipated Adverse Events  
Those known adverse events and surgical interventions related to the device or procedure are 
extrapolated from a population of 299 patients who underwent DBS for movement disorders 
(Medtronic® DBS™ Therapy for Parkinson’s Disease and Essential Tremor CLINICAL 
SUMMARY, 2013):
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 26 of 39 • Abnormal behavior  
• Abnormal dreams  
• Activities of daily living 
impaired  
• Adverse drug reaction  
•  Agitation  
• Akinesia  
• Anemia  
• Anxiety  
• Aortic stenosis 
• Appendicitis perforated  
• Arteriosclerosis  
• Arthralgia  
• Arthritis  
• Asthenia  
• Asthma  
• Back pain  
• Balance disorder 
• Benign prostatic hyperplasia  
• Biopsy bone  
• Bladder catheter removal  
• Blood pressure increased  
• Bone Fractures  
• Bone graft  
• Bradykinesia  
• Breast cancer  
• Bronchitis  
• Burns third degree 
• Cardiac pacemaker insertion  
• Cartilage injury 
• Cellulitis  
• Cerebral haematoma  
• Cerebral haemorrhage 
• Cerebrovascular accident  
• Chest discomfort  
• Chest pain  
• Cholelithiasis  
• Clostridium difficile colitis  
• Clostridium difficile sepsis  
• Cognitive disorder  
• Complication of device removal  
• Confusional   state • Constipation  
• Convulsion  
•  Cough  
• Debridement  
• Decubitis ulcer 
• Deep vein thrombosis  
• Deep vein thrombosis postoperative  
• Dehydration  
• Delirium  
• Delusion  
• Delusional disorder, 
persecutory type  
• Depression  
• Depression suicidal  
• Device electrical finding  
• Device failure  
• Device migration  
• Diabetic ketoacidosis  
• Diverticulitis  
• Dizziness  
• Drooling  
• Drug hypersensitivity  
• Drug toxicity  
• Dysgraphia  
• Dyskinesia  
• Dysphagia  
• Dyspnoea  
• Dystonia  
• Dysuria  
• Erectile dysfunction  
• Fall  
• Fatigue  
• Freezing phenomenon  
• Gait disturbance 
• Gastric polyps  
• Gastroduodenitis  
• Gastrointestinal disorder  
• Gastrooesophageal 
reflux disease  
• Glioma  
• Grand mal convulsion  
• Haematoma  
• Haemoglobin decreased  
• Haemorrhage intracranial  • Hallucination  
• Head injury  
• Headache  
• Hiatus hernia  
• Hip arthroplasty  
• Homelessness 
• Hyperhidrosis  
• Hyperkalaemia 
• Hypertension  
• Hypoaesthesia  
• Hypotension  
• Hypovolaemia  
• Hypoxia  
• Implant site erosion  
• Implant site infection 
• Implant site reaction  
• Incision site complication  
• Incision site pai n 
• Inguinal hernia  
• Insomnia  
• Intestinal obstruction  
• Intestinal perforation  
•  Intraventricular 
haemorrhage 
• Labile blood pressure  
• Labile hypertension 
•  Lethargy  
• Localized infection  
• Lumbar spinal stenosis 
• Lung neoplasm 
malignant  
• Major depression  
• Malnutrition  
• Mechanical complication of implant  
• Mediastinal 
haemorrhage   
• Medical device complication  
• Medical device discomfort  
• Medical observation  
• Memory impairment  
• Meniscus lesion  
• Mental status changes 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 27 of 39 • Mental status changes 
postoperative  
• Metabolic 
encephalopathy  
• Mobility decreased  
• Motor dysfunction 
• Muscle rigidity  
• Muscle spasms  
• Musculo -skeletal pain  
• Musculo -skeletal 
stiffness  
• Musculoskeletal chest pain 
• Nausea  
• Neck pain  
• Neuropathy peripheral  
• Oedema peripheral 
• Oesophageal spasm  
• Oesophagitis 
• Orchitis  
• Orthostatic hypotension  
• Osteoarthritis   
• Pain  
• Pain in extremity  
• Paraesthesia  
• Parkinson’s disease  
• Perseveration  
• Pleuritic pain  
• Pneumocephalus  
• Pneumonia   • Pneumonia aspiration  
• Pollakiuria  
• Poor quality sleep  
• Post-traumatic stress 
disorder  
• Procedural complication  
• Procedural pain  
• Prostate cancer  
• Prostate cancer metastatic   
• Psychotic disorder  
• Pyelonephritis  
• Pyrexia  
• Rapid eye movements sleep abnormal  
• Rash  
• Rectal haemorrhage  
• Rectocele  
• Restless legs syndrome 
• Retinal detachment  
• Reversible ischaemic neurological deficit  
• Road traffic accident  
• Rotator cuff repai r 
• Rotator cuff syndrome  
• Scar pain  
• Self-medication   
• Sepsis  
• Sexual dysfunction  
• Sialoadenitis  • Small intestinal 
obstruction  
• Somnolence  
• Speech disorder  
• Subdural haematoma  
• Suicidal ideation  
• Suicide attempt  
• Syncope  
• Syncope vasovagal  
• Tooth abscess  
• Transient ischaemic 
attack  
• Treatment noncompliance  
• Tremor  
• Upper respiratory tract infection  
• Urethral injury  
• Urethral stenosis  
• Urinary incontinence 
• Urinary tract infection  
• Urosepsis  
• Viral infection  
• Visual disturbance 
• Vomiting  
• Weight decreased  
• Weight increased  
• Wound dehiscence 
 
The known or expected adverse effects that are attributable to stimulation are the following:
• Paresthesia  
• Diplopia 
• Dysarthria  
• Dysequilibrium 
• Paresis  
• Dystonia 
• Gait disorder 
• Electrical shocking or jolting  
• Headaches  
• Pain, discomfort or local stress  
• Attention deficit  
• Dysphasia 
• Insufficient therapeutic effect  • Ataxia  
• Dyskinesia  
• Sensory deficits 
• Suicidal ideation  
• Mania or hypomania 
• Facial weakness  
• Fatigue 
• Loss of energy 
• Numbness 
• Other speech deficits  
• Rebound symptom worsening with 
discontinuation of stimulation 
• Transient heaviness in arm  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 28 of 39 • Changes in blood pressure or heart 
rate 
• Nausea or vomiting 
• Rapid or shallow breathing 
• Anxiety 
• Apathy 
• Agitation  
• Aggression 
• Asthenia • Balance disorder  
• Akinesia 
• Bradykinesia 
• Chest discomfort  
• Seizures  
• Weight gain or weight loss  
• Somnolence 
• Tremor  
• Undesired change in libido 
 
9.4.2. Unanticipated adverse device effects (UADEs)  
An unanticipated adverse device effect is “any serious adverse effect on health or safety or any 
life-threatening problem or death caused by, or associated with, a device, if that effect, problem, 
or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects” [21 CFR 812.3(s)]. Unanticipated means the event is not listed in the 
labeling, or the frequency or severity is greater than that reported in the labeling. 
9.5. Adverse Event Reporting  
Since we do not know in advance what, if any, adverse effects deep brain stimulation may have in this patient population, we will record and code any adverse clinical event on the Adverse 
Event form, whether it is mild or severe, and regardless of whether it is likely to be stimulation related or not.  The AE forms will subsequently be analyzed to empirically determine which AEs 
are likely to be due to or exacerbated by the stimulation.  We have developed specific procedures 
for coding AEs and have developed guidelines for breaking the blind should this be viewed as necessary by the treating physician.  These procedures and guidelines are described below:  
Two types of AE’s be recorded: 
• A new onset AE refers to the onset of an abnormality in a patient previously 
determined to have normal function in that area.  This would include such things as 
the onset of spasticity in a patient who had normal tone previously, or the 
development of a tremor in someone who had active movement without a tremor before.    
• A worsening AE involves either an increase in severity of some symptom or some deterioration of function or ability.   This would include such things as worsening 
hypertonia in someone who already had hypertonia.  This category should be used 
once an adverse event has already been recorded, t o indicate subsequent worsening of 
that adverse event.  
Note that many AEs are, by their nature, chronic events with waxing and waning courses (e.g., behavioral dyscontrol) while others are discrete single events (e.g., development of a DVT).  
Chronic patterns will be reported as AEs only if their pattern of occurrence changes (i.e., the episodes become more frequent or severe), and will be considered resolved when the pattern 
returns to the pre -treatment baseline.  New onset AEs which may become chronic pat terns (i.e., a 
first episode of aggression) will be identified as starting at the time of the first event.  AEs which 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 29 of 39 have no clear date of resolution but require long- term treatment will be considered ongoing until 
that treatment is completed (e.g., DVT w ith anticoagulant prophylaxis, osteomyelitis with 
prolonged antibiotic treatment).  
In addition to recording descriptive information about the AE on the form, AEs will be 
characterized as anticipated or unanticipated (based on the previously- established side effect 
profile), a severity rating (reflecting seriousness and impact on clinical status) will be assigned, 
and the probability that the AE was related to the study treatment will be estimated (based on the 
plausibility to the known clinical effects of n eurostimulation, and knowledge of other clinical 
risk factors for the AE).  We will also indicate whether treatment of the AE was required, 
whether the study treatment was changed as the result of the AE, the date the AE resolved and the outcome of the AE. 
9.5.1. Reporting Serious Adverse Events 
The Sponsor- Investigator will direct all study personnel to inform him as soon as possible 
(within 24 hours) of any serious adverse event.  If necessary, study personnel may communicate 
by telephone or e- mail, and follow -up later with completed case report forms.  The Sponsor-
Investigator will conduct an evaluation of the event and if it is determined to be a UADE, it will 
be reported as described in the following section.  
9.5.2. Reporting UADEs  
If an event is determined by the Sponsor-Investigator to be a UADE, he will report the event to 
the FDA and the IRB within the required timeframe of 5 business days if death or life 
threatening, and 10 business days if other serious criteria are met.  
9.5.3. Stopping Rules  
If two of the six study participants experience either a serious UADE or an adverse device effect 
that the Sponsor -Investigator determines would present an unreasonable risk to other participants 
enrolled in the trial, the Sponsor -Investigator must terminate the clinical trial 5 d ays after making 
that determination and not later than 15 days after the Sponsor- Investigator first receive notice of 
the effect.  
9.5.4. Reporting Deaths and Suicides  
For any death that occurs during the course of the study, the sponsor will notify the IRB within an expedited timeframe according to the following guidelines: 
• R
eport the event within 24 hours when the death is unforeseen (unexpected) and 
indicates participants or others are at increased risk of harm.  
• Report the event within 72 hours, for all other de at hs, regardless of whether the death 
is related to study participation. 
The sponsor will notify the FDA within 5 business days as noted above.  
10. CLINICAL OVERSIGHT COMMITTEE  
It is the responsibility of the Sponsor-Investigator to oversee the safety of the study participants.  
This includes careful assessment and appropriate reporting of adverse events as noted above.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 30 of 39 In addition, a Clinical Oversight Committee (COC) has been appointed to conduct ongoing 
reviews of the safety of the Study and make recommendations regarding changes to the risk/benefit of the Study, including recommendations to discontinue new patient enrollments or 
discontinue the Study.  The COC will review all SAEs as they occur and will conduct routine 
reviews at least quarterly throughout the study. 
10.1. Medical Monitor  
An Independent Medical Monitor has been designated for this study to regularly assess reports of 
unanticipated study- related events.  Once per quarter the Medical Monitor will review reports of 
any study- related unanticipated adverse events.  The Clinical Oversight Committee will convene 
an ad hoc meeting to review any report of an unanticipated adverse e vent that is both study-
related and serious. 
11. STATISTICAL PLAN   
This is a feasibility study to in form the  safety and eff icacy of centra l thalamic-deep brain 
stimulation (CT-DBS) in the  treatment of chr onic cognitive  impairment and re sidua l disability 
caused by trauma tic bra in injury (TBI).  The primary outcome measure used will be the Trail 
Making test and secondary outcome measures include measures of cognition (Ruff 2 & 7), physical symptoms (Rivermead  Post -Concussion Symptom Questionnaire (RPQ)), psychological 
health (Patient Health Questionnaire -9 and Columbia Suicide Severity Rating Scale (C- SSRS), 
quality of life (Traumatic Brain Injury Quality of Life (TBI -QoL subscales)), and measure of 
global function (Glasgow Outcome Scale- Extended (GOSE)).  For the prese nt stu dy all base line, 
procedura l, and s afety and effectiveness follow -up da ta will be  summ arized with appropria te 
descriptive  statistics.  F or continuous v ariables we will summ arize da ta by the m ean, m edian, 
standard de viation, minimum and max imum.  For non-continuous var iables we will summar ize 
by pe rcentage s and frequenc y dist ributions.  We will ta bulate data for a ll enrolled pa tients.  Our 
statistical analysis will be limited due to the small sample size.  
Expl
ora tory statistical analyse s of pr imary and secondary endpoints will be perf orme d to ide ntify 
potentia l relationships be tween the trea tment and the outc ome variables.  
Adverse event da ta will also be reported a nd tabulated. 
12. RISK ASSESSMENT AND MITIGATION  
12.1. Known and Anticipated Surgical Risks  
The Sponsor-Investigator (who will also be the implanting surgeon in this study) is an 
experienced functional neurosurgeon with nearly 20 years’ experience with deep brain stimulation.  He was one of the original investigators in the first trial of DBS for movement 
disorders in the US (“Clinical Investigation of Deep Brain Stimulation for Treatment of Tremor Using the Medtronic Model 3382 DBS,” 1996-1999).    He will perform the surgical procedures in this study using his standard technique, developed in over 600 successful implants.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 31 of 39 12.2. Device- Related and Therapy- Related Risks  
Co-Investigators Nicholas Schiff, Joseph Giacino, and Andre Machado were all involved in the 
original trial of CT -DBS for the treatment of the minimally conscious state (MCS).  Drs. Giaci no 
and Schiff are world experts in traumatic brain injury.  They will direct parameter selection for 
DBS programming and will consult on targeting of the CT along with Drs. Machado and Butson, 
both of whom have extensive experience in targeting this region. 
The inclusion/exclusion criteria have been developed to exclude participants with concurrent 
illnesses that could increase the risk of DBS placement, as well as major developmental, neurologic, psychiatric or substance use disorders that may confound interpretation of results.  
Participants for whom DBS implants are contraindicated are excluded from study participation 
(e.g., a medical condition requiring MRI, and/or exposure to diathermy). 
Participants will be counseled that they are not to undergo an MR I examination or shortwave 
diathermy as long as the DBS system is implanted.  
12.3. Protocol for Managing Suicidal Ideation and Intent 
All study personnel will be provided with the following protocol for managing suicidal ideation 
and intent.  Participants will be closely monitored for any suicidal thoughts or plans during all 
study interactions, including telephone calls and in-person visits. 
If the participant endorses an item suggesting suicidal ideation on any self- report questionnaire, 
or reports suicidal ideation at any time during participation in the study, immediately administer 
questions 1 and 2 from the Columbia Suicide Severity Rating Scale (CSSRS).  Proceed with administering items as needed according to the instructions for that scale.   Based on the 
participant’s responses, follow one of the following procedures.  
1. Sc
enario 1: Participant responds “no” to question 2 on C -SSRS (“Have you actually 
had any thoughts of killing yourself?”) 
Empathize with how hard things have been for them and let them know that it is not unusual for people to have these thoughts when they have experienced TBI.  Encourage them to talk to a family member or friend when they feel this way.  Also provide them 
with a crisis line number and encourage them to phone if they ever start thinking about 
actually killing themselves.  Proceed with the study protocol.  
2. S
cenario 2: Participant responds “yes” to question 2 on C-SSRS (“Have you 
actually had any thoughts of killing yourself?”) AND answers “no” to question 3 
(“Have you been thinking about how you might kill yourself?”)  
Empathize with how hard things have been for them and let them know that it is not 
unusual for people to have these thoughts when they have experienced TBI.  Encourage 
them to talk to a family member or friend whe n they feel this way.  Also provide them 
with a crisis line number and encourage them to phone if they ever start thinking about 
actually killing themselves.  Proceed with the study protocol.  
3. S cenario 3: Participant responds “yes” to question 3 on C- SSRS (“Have you been 
thinking about how you might kill yourself?”) AND answers “no” to question 4 
(“Have you had these thoughts and had some intention of acting on them?”).  
Discuss a safety plan with the participant.  If you are meeting with the participant in  
person, have them complete the safety plan themselves, providing guidance as necessary.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 32 of 39 Then have the participant sign it and ask the study physician or a licensed psychologist 
on the team to review the plan with them.  Provide them with the crisis line information by writing it on the safety plan.  If you are talking with the person by phone, go over the 
safety plan, asking them to generate responses to the items, while providing guidance as 
necessary.  Record their responses and then ask the study physi cian or a licensed 
psychologist on the team to review the plan with them.  Send them a copy by mail, 
provide the contact information for the crisis line verbally over the phone and write it on 
the safety plan before mailing.  
4. S
cenario 4: Participant responds “yes” to question 3 on C- SSRS (“Have you been 
thinking about how you mig ht kill yourself?”) AND either answers “yes” to question 
4 (“Have you had these thoughts and had some intention of acting on them?”) or is 
equivocal regarding whether they intend to act on their thoughts.  
Ensure that they are safe at the moment.  This means that they are not in imminent danger of harming themselves and do not have guns, knives or other weapons available to use.  If you cannot deem that they are safe, ask their permission to speak with a fam ily member 
who is with them.   Tell the family member that they should stay with the patient and 
should make sure that they are safe, provide them with the crisis line number, advise them to take the person to an emergency room if possible, and advise them to call 911 if 
they fear that they cannot stop the person from hurting themselves and cannot talk them 
into going to the emergency room.  If there is no family member present, or they refuse to have you speak with one, and you cannot deem that they are safe, maintain them on the 
line and ask the study physician, another research team member or an administrative 
assistant to call 911 and ask that the police visit the participant at their current location.  Meanwhile, ask the participants’ permission to conne ct them to a crisis line so that they 
can talk with someone who is trained to help them through the crisis.  If they agree, connect them to the crisis line.  
NOTE: Occasionally, someone may withhold permission for you to transfer them to a crisis line.  
If this refusal appears to be due to fear, uncertainty, or embarrassment, then talk them through 
the reasons for the crisis line and ask their permission again.  If they still refuse, or if they appear 
to simply want to stay on the line talking with you, tell them that for their own safety, you need 
to connect them to the crisis line.  Ask them to stay on hold while you dial the crisis line.  Make 
sure that they have your telephone number so that they can call you back in case you are disconnected.  You may call them back if you are disconnected.  If you are unable to reach them, 
and you deem that they are in imminent danger of harming themselves, then call 911 and ask the 
police to visit the person at their current location.   
NOTE:  The same protocol can be applied to a person who endorses suicidal ideation and intent 
during an on- site assessment.  Simply have them call the crisis line from a nearby office.  
REMEMBER TO DOCUMENT EACH STEP THAT YOU PERFORM, HAVE THE 
SPONSOR -INVESTIGATOR OR HIS DESIGNEE (EG, STUDY PHYSICIAN, 
PSYCHOLOGIST) REVIEW THE SAFETY PLAN AND PLACE IT IN THE PARTICIPANTS’ RESEARCH FILE.  
The process for connecting on- line telephone participant to crisis line:  
While on the phone with the participant, ask them to hold while you connect them t o the 
crisis line (or use the conference- calling feature, if available):  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 33 of 39 Crisis Line #:  1-800-273- TALK (8255) National Suicide Prevention Lifeline    
   1-888-628-9454 (Spanish) 
Be sure that they have been connected to a crisis counselor before hanging up. 
13. Administrative Requirements, including Investigator Responsibilities  
13.1.  Good Clinical Practice (GCP)  
The study will be conducted in accordance with, but not limited to, 21CFR parts 812, 11, 50, 54, 
56 and ICH - GCP .  The Investigator will be thoroughly familiar with the appropriate use of the 
study product as described in the protocol and Directions for Use.  Essential study documents 
will be maintained to demonstrate the validity of the study and the integrity of the data collected.  
Trial Master Files will  be established at the beginning of the study, maintained for the duration 
of the study and retained according to the appropriate regulations and SOPs.  
13.2. Ethical Considerations  
The study will be conducted in accordance with ethical principles founded in the Declaration of 
Helsinki.  IRBs will be provided all relevant study documents in order to safeguard the rights, safety, and well -being of the subjects per their mandate.  This study will be implemented only at 
sites where IRB approval has been obtained.  The protocol, Product Literature, informed consent, written information given to the subjects, safety updates, and any revisions to these documents will be provided to the IRB by the Investigator.  
13.3. Subject Information and Informed Consent  
After the study has been fully explained to the potential subject, written informed consent will be obtained prior to the performance of any study- related procedures.  The method of obtaining and 
documenting the informed consent and the contents of the consent will comply with ICH- GCP 
and all applicable regulatory requirements, including local IRB requirements.  
It is understood that Informed Consent is a process and not an event.  The Investigator is 
responsible for maintaining an ongoing, open dialog with the subject in regards to their 
continued participation in the study. 
13.4.  Subject Confidentiality  
In order to maintain subject privacy, CRFs , study product accountability records, study reports 
and communications will identify the subject by initials and the assigned subject number only.  The Investigator will grant monitor(s) and/or auditor(s) from regulatory authorities’ access to the 
subjec t’s original medical records for verification of data recorded in the CRFs  and to audit the 
data collection process.  The subject’s confidentiality will be maintained and no Protected Health 
Information will be disclosed, other than that which is described in the Informed Consent Form.  
13.5. Protocol Compliance  
Strict adherence to the protocol is expected.  However, there are times when this is not possible.  
Any failure to follow the protocol (i.e. a deviation) mus t be identified and recorded.  Deviations 
from the protocol which:  ( 1) increase subject risk or (2) impact on study endpoints, will be 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 34 of 39 considered protocol violations.  Protocol deviations and violations will be tabularized in the data 
listings.   
Substantive changes to the protocol will require writt en FDA and IRB approval prior to 
implementation, except when such departures are necessary to eliminate an immediate hazard(s) 
to subjects.  The IRB may provide expedited review and approval for minor change(s) in ongoing studies that have the approval of the IRB.   
13.6. Maintenance of Study Records  
The Investigator is responsible for maintaining adequate and accurate study records.  These may include, but are not limited to:  Screening, Consent and Enrollment Logs, staff training records, 
licenses & certificati ons, correspondence between Investigator and Sponsor and/or IRB, financial 
disclosures, investigator agreement, Product Accountability Logs, Protocol Signature Pages, 
authorization forms and other study related documents. 
13.7. Study Monitoring  
The Sponsor /Investigator  will oversee and monitor the progress of the Clinical Study to assure 
that it is conducted, recorded, and reported in accordance with the Clinical Protocol, written procedures, agreements, and applicable regulations.  This will be acco mplished by: 
• Ensuring proper informed consent and the protection of the rights and well-being of 
study subjects 
• Assessing data integrity  
• Identifying and addressing non- compliance issues 
• Identifying research misconduct or fraud  
• Reviewing essential documents and approvals  
• Assessing overall site capabilities  
• Ensuring device accountability is maintained 
13.8. On-Site Audits  
Regulatory authorities or the IRB, may request access to all source documents, eCRFs, and other 
study documentation for on- site audit or inspect ion.  Direct access to these documents must be 
guaranteed by the Investigator, who must provide support at all times for these activities.  
13.9. Case Report Form Completion  
Case Report Forms will be completed for each subject enrolled in the study.  It is the 
Investigator’s responsibility to ensure the accuracy, completeness, and timeliness of the data 
reported in the subject’s CRF.  Source documentation supporting the e CRF data must indicate 
the subject’s participation in the study and document the dates and details of study assessments, 
inter- current procedures, and adverse events.  
The Investigator will be provided a copy of all completed CRF pages.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 35 of 39 13.10.  Study Product Accountability  
Accountability for the study product and other clinical study supplies at each s ite participating in 
this study is the responsibility of the Investigator and appropriate records of receipt of product 
will be maintained.  The Investigator will ensure that the study product is used only in 
accordance with this protocol and is maintained  under appropriate IDE (21CFR 812) conditions.  
14. REFERENCES  
1. Baker, JL, Ryou, JW, Wei, X, Butson, C, Schi ff, ND, and Purpura , KP (2011) 
Modula tion of globa l beta osc illations within the frontal- striatal-ce ntral thalamic network 
during sustained attention. Society for Neuroscience Abst ract 197.26. 
2. Baker, JL, Ryou, JW, Wei, X, Butson, C, Schi ff, ND, and Purpura , KP (2012) Beha viora l 
modula tion with central thalamic deep brain stimul ation in non-human pr imates. Society 
for Neuroscience Abst ract 597.14. 
3. Bronte-Stew art H, Louie S, Batya S, Hend erson JM. (2010) C linica l motor outcome of 
bilateral subth alamic nucleus dee p-brain stimulation for P arkinson's disea se using image-
guided fra mele ss stereotaxy. Neur osurgery 67:1088–93; discussion 1093. 
4. Co rrigan J D, Sela ssie AW, Orman J A. (2010) The epide miolo gy of t raumatic brain 
injury. J H ead Trauma Rehabil. M ar-Apr;25(2):72-80. 
5. Corrigan J D, Cuthber t JP, H arrison- Felix C, Wh iteneck G G, Be ll JM, Mi ller AC, e t al. 
(2014) US Popula tion Estimates of H ealth and Socia l Out comes 5 Y ears After 
Rehab ilitation for T raumatic Brain Injury. J H ead Trauma Rehabil.29(6) :E1-9. 
6. Dikm en SS, M achamer J E, Powe ll JM, Temkin NR. (2003) Out come 3 to 5 ye ars after 
mode rate to severe traumatic brain injury. A rch Phy s Med Rehabil. Oc t;84(10):1449-57. 
7. Duncan J , Owen AM. (2000) Common re gions of the human fronta l lobe  recruited by 
diver se cog nitive d emands.T rends Neurosci. Oc t;23(10):475-83. 
8. Fan J, McCandliss BD, Sommer T, Raz A, Posner M. Testing the efficacy and independence of attentional networks. (2002)  J Cogn Neurosci 2002 14(3): 340-347. 
9. F
ridman, EA, Beattie BJ, Broft A, Laureys S, Schiff ND. (2014) Regional cerebral 
metabolic patterns demonstrate the role of anterior forebrain mesocircuit dysfunction in the severely injured brain. Proc Natl Acad Sci  Apr 29; 111 (17): 6473-8. 
10. Giacino J, Fins JJ , Machado A, Schiff ND. (2012) Cent ral thalamic deep br ain 
stimulation to promote recovery fr om chronic postt raumatic minimally c onscious state : 
challenge s and oppor tunities. Neuromodula tion. 15(4):339-49. doi: 10.1111/j.1525-
1403.2012.00458.x. Epub 2012 May 24. 
11. Heaton R, Miller SW, Taylor MJ and Grant I. (2004) Revised Comprehensive norms for an Expanded Halstead- Reitan Battery: Demographically -Adjusted Neuropsychological 
Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessment 
Resources, Inc.  
12. Holloway KL, Gaede SE, St arr PA, Rosenow J M, Ramakr ishnan V, Henderson J M. 
(2005) Fra mele ss stereotaxy using bone fiducia l mar kers for deep bra in stimulation. 
Journa l of Neurosurger y 103:404–413.  
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 36 of 39 13. Jeanmonod D1, M agnin M, Mo rel A. (1996) Low- threshold ca lcium spike  bursts in the  
human thalamus. Common physiopathology for sensory, motor  and limbic positive 
symptoms. Brain. Apr;119 ( P t 2):363-75. 
14. Levin HS, L i X, McCauley SR, Hanten G, W ilde EA, Swank P.Neuropsychologi cal 
outcome of mT BI: a princ ipal component analy sis approac h. J Neurot rauma. 2013 Apr 
15;30(8) :625-32. doi: 10.1089/neu.2012.2627. Epub 2013 Mar 4. 
15. Machado a, Rezai AR, Kopell BH, Gross RE, Sharan AD, Benabid AL.  Deep brain 
stimulation for Parkinson’s disease: surgical technique and perioperative management. Mov Disord 2006; 21 Suppl 14:S247- 58. PMID: 16810722 
16. Mair RG, Onos KD, He mbrook JR. (2011) Cog nitive  activation by centra l thalamic 
stimula tion: the yerkes-dodson la w revisited. Dose Response. 9(3):313-31. doi: 
10.2203/dose- re sponse .10-017. 
17. Maxwe ll, W.L., Mac Kinnon, M.A., Smith, D.H., McIntosh, T.K. & G raham, D.I. (2006) 
Thalamic nucle i after human blunt h ead injury. J Neuropa thol E xp Neurol, 65, 478-488. 
18. McCor mick DA, Shu Y, Hasensta ub A, Sanchez- Vives M, Badoual M, Ba l T. (2003) 
Persistent cor tical activity: mec hanisms of gen eration and effects on neurona l exc itability. 
Cereb Cortex. 2003 Nov;13(11):1219-31. 
19. Murr
 ay CJ, Lopez AD. (1997) A lternative projections of mortality and disa bility by cause 
1990- 2020: Globa l Burden of Disease S tudy. Lan cet. May 24;349(9064):1498-504. 
20. Purpura , K. and Schiff, N.D. (1997) The thalamic intralaminar nucle i: a role in visua l 
awarene ss. The  Neuroscie ntist 3:8 -15. 
21. Schiff, N.D. and Plum, F. (2000) The role of arousa l and ‘ga ting’ sy stems in the  
neurol ogy of imp aired consciousne ss. Journal of C linical N europhy siology 17(5) : 438 -
452. 
22. Schiff , ND Gi acino, J.T., Ka lmar, K., Vic tor, JD, Baker, K, G erber, M, Fritz, B, 
Eisenberg, B, Biondi, T, O’Connor, J , Kobylarz , EJ, Farr is, S, M achado, A, Mc Cagg , C, 
Plum, F, Fins, JJ, and Rezai, AR. (2007) Behavio ral imp roveme nts with th alamic 
stimula tion after sever e traumatic brain inju ry. Na ture 448:600-603. 
23. Schiff , ND (2008) Centra l thalamic contr ibutions to arousal regulation and neurologi cal 
disorder s of consciousness. Anna ls of New York Academy of Sciences 1 129: 105-118. 
24. Schiff, N.D. (2009) Cent ral thalamic deep bra in stimula tion: mecha nisms and ra tionale 
for treatment of non-prog ressive b rain injury. Annals of New York Academy of Scien ces 
1129:105-118. 
25. Schiff, ND. (2010) R ecovery of consciousne ss after bra in inju ry: a mesocirc uit 
hypothe sis. T rends in Neuroscience 33(1) :1-9. 
26. Schiff ND. (2012) Moving toward a genera lizable appli cation of central thalamic deep 
brain stimul ation f or support of fore brain arousal regula tion in the  severely injured bra in. 
Ann N Y Aca d Sci. 1265:56-68. d oi: 10.1111/j.1749-6632.2012.06712.x. Epub 2012 Jul 
26. 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 37 of 39 27. Selassie AW, Zaloshnja E, Lang lois J A, Mi ller T, Jone s P, Ste iner C. (2003) Inc idence of 
long- term dis ability following t raumatic brain inju ry ho spitalization, United States, 2003. 
J Head T rauma Reha bil. 2008 Mar-Apr;23(2):123-31. 
28. Shirva lkar, P., Seth, M. Schi ff, N.D., H errera, D.G. (2006) Cog nitive  enhan cement with 
centr al thalamic electrical stimulation. Proceedings of the Na tional Academy of Scien ces 
103(45): 17007-17012. 
29. Smith, A C, Shah, S , Hudson, AE, Purpura , KP, Vic tor, JD, Brown, EN, Schi ff, ND. 
(2009) State- space and parametr ic models for charact erizing behaviora l facilitation 
associated with deep bra in stimulation. J Neurosc i Methods. 183(2):267- 76. 
30. Stuss DT, Knight, RT, eds. Pr inciples of Frontal Lobe Function. New York: Oxford 
Univ ersity Press, 2013.  
31. TBI Mode l Systems N ationa l Data and Sta tistical Cent er. Traumatic brain injury mode l 
systems n ational database. http://www.tbindsc.org 
32. Tourdias T, Sarana than M, Leve sque IR, Su J, R utt B K. (2013) Visu alization of int ra-
thalamic nucl ei with optimized white-ma tter-nulled M PRAGE at 7T. Neuroimage , 1–39 
33. Tucker, DM. (1993) Spatial sampling of head electrical fields: the geodesic sensor net. 
Electroencephal Clin Neurophys 87:154-163. 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 38 of 39 APPENDIX 1. DEVICE PROGRAMMING SOP  
Programming of the device will utilize standard DBS techniques for assessing effects and side 
effects during a cathode survey of the DBS leads.  Programming will be conducted under the 
direct supervision of Dr. Henderson or under the direct supervision of personnel trained by Dr. 
Henderson.  Dr. Henderson will review and sign all forms summarizing adverse events observed during stimulation programming.  
The primary purpose of DBS programming is to select the optimal chronic stimulation 
parameters to use during stimulation titration and chronic stimulation.  Dr. Henderson may consult with other investigators to select the best stimulation parameters but will be responsible 
for the final decision based on effects and adverse effects.  Given the nature of this study, the 
selection of initial stimulation parameters for testing will be partially based on available animal data from Dr. Schiff’s laboratory as well as the group’s prior experience in deep brain 
stimulation in patients with traumatic brain injury.  Based on this combined experience, it is 
expected that stimulation frequency will be set in the range of 130-185 Hz. Final selection of chronic frequency, active contacts, pulse widths and amplitudes will be based on the titration 
testing using a systematic cathode survey as outlined below.  
A cathodal survey will be performed by activating, in a systematic fashion, each of the four 
contacts in each DBS lead as the cathode.  All patients will have bilateral deep brain stimulation 
and the investigators will first test the effects of stimulation on the left side lead and then test the 
right side separately.  Bilateral stimulation will only be attempted after e ach side has been tested 
individually.  All stimulation testing will be conducted below the safe change density limit of 30 
μC/cm
2/phase.  
Each contact on each lead will be tested as the cathode (with the IPG set as the anode).  
Amplitude will be tested with stepwise increments in amplitude from 0 to a maximum of 10 V. 
Amplitudes will be increased until acute effects are noted or reported by the patient or the charge 
density limit is reached.  Pulse widths will be initially set at 60 microseconds and will n ot exceed 
120 microseconds.  The investigators will look for and ask about the following acute effects but 
will also ask the patient to report any subjective changes: 
• Paresthesias or pain  
• Motor changes such as twitches, dystonia, changes in posture  
• Verbal Fluency 
• Speech changes 
• Mood and anxiety 
• Alertness or energy level  
• Occulomotor changes or diplopia 
• Behavioral changes 
While mild or transient sensory changes such as mild paresthesias may allow stimulation 
titration to continue, unpleasant effects such as pain, motor effects or occulomotor effects will 
prompt the investigators to no longer increase stimulation amplitude, at which time it will be 
recorded that the Threshold for side effect was identified with that given electrical contact as the 
cathode.  Likewise, positive effects such as improvements in energy or alertness will be recorded 
CT-DBS Clinical Protocol, Ver 7 
  
CONFIDENTIAL   Page 39 of 39 and the lowest amplitude that produces desirable effects will be recorded as the Threshold for 
positive effects.  Once the cathode survey is completed, the investigators will select the electrical contacts that produce the most robust positive effects at the lowest amplitudes and negative 
effects at the highest amplitudes (i.e. therapeutic index) for chronic stimulation.  It is relevant to 
notice that the initial cathode survey will only provide the initial guidance for stimulation adjustment.  Because the cathode survey is typically conducted over a session of 2-3 hours, it 
does not account for tempor al summation of effects.  If adverse effects are reported over days or 
hours, further programming will be needed in order to identify the parameters that produce the 
intended b enefits with limited adverse effects.
 